ARCH Venture Fund X, L.P. (CRANDELL KEITH, Burow Kristina) purchased $2.0M of ASPE

ARCH Venture Fund X, L.P. purchased 1,200,000 indirectly-held shares of Aspen Neuroscience, Inc. (ASPE) at $15.00 ($18.00M total) on 2026-11-02. Filed jointly with ARCH Venture Fund X Overage, L.P. (10% owner), ARCH Venture Partners X, L.P. (10% owner), ARCH Venture Partners X Overage, L.P. (10% owner), ARCH Venture Partners X, LLC (10% owner), CRANDELL KEITH (10% owner), Burow Kristina (10% owner), GILLIS STEVEN (10% owner) and NELSEN ROBERT (10% owner).

ARCH Venture Partners XIV, L.P. purchased 1,200,000 shares of Aspen Neuroscience, Inc. (ASPE) at $15.00 ($18.00M total) on 2026-11-02. Filed jointly with ARCH Venture Partners XIV, LLC (10% owner), ARCH Venture Fund XIV, L.P. (10% owner) and BERNS PAUL L (10% owner).

Aspen Neuroscience, Inc. (ASPE) filed an SEC Form 8-K — Other Events. Item 5.03 Amendments to Certificate of Incorporation or Bylaws; Change in Fiscal Year. On November 2, 2026, in connection with the closing of the initial public offering (the “ IPO ”) of Aspen Neuroscience, Inc. (the “ Company ”), the Company’s amended and restated certificate of

Aspen Neuroscience plans to raise $140.6M via IPO, offering 9.375M shares at $15 each. The company, developing Parkinson's disease cell therapy sasineprocel, will list on Nasdaq under ASPE. Proceeds will fund clinical trials and working capital. The company reported a $36.5M net loss for the first half of 2026.

Aspen Neuroscience (ASPE) raised $140.6M in its Nasdaq IPO, pricing shares at $15. The proceeds will fund its Parkinson's disease cell therapy pipeline. Five banks led the offering, aiming to diversify its shareholder base. The company's clinical pipeline is now under increased scrutiny from analysts and shareholders.

Aspen Neuroscience (ASPE) priced its IPO at $15 per share, raising $140.6M from 9.375M shares. The company may issue 1.406M more shares within 30 days. Latham & Watkins advised the underwriters.